eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention... a senior northern ireland civil servant has apologised after hundreds of neurology patients were recalled for further testing....
"our protocol says if you are suspicious for lyme disease, you start treating", said rusk..
..
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital..
., seventh-highest in the nation, and more than double the national average..
. a senior northern ireland civil servant has apologised after hundreds of neurology patients were recalled for further testing....
.
.